Avillion notes that Pfizer have received a positive CHMP opinion for BOSULIF® (bosutinib) for treating newly-diagnosed Ph+ chronic myelogenous leukemia.
The filing is based on the successful BFORE Phase 3 study conducted by Avillion under a collaborative development agreement with Pfizer.
Please read the full press release here.